



anti-HPV E7₁₁₋₁₉ T Cells
Catalog Number: 1099
Lot Number: 4509NV19

Certificate of Analysis

Cell count 2 million per vial
Viability 96%

Donor Information

Donor ID 224
Age 52
Gender Female
Race Caucasian
Height 5'3"
Weight 180
ABO Type B negative

HLA typing

	Allele 1	Allele 2
HLA-A	*0201	*0201
HLA-B	*07	*15
HLA-C	*03	*07
HLA-DRB1	*13	*15

Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures


FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE

Astarte Biologics, LLC

425-481-4180

astartebio.com

IFN-gamma Secretion



20,000 T cells were plated in a 96-well round-bottom plate alone or in the presence of 20,000 T2 cells (a B-LCL expressing HLA-A*0201), alone or in the presence of increasing concentrations HLA-A*0201 restricted HPV E7₁₁₋₂₀ peptide (YMLDLQPETT), HLA-A*0201 restricted HPV/E7₁₁₋₁₉ peptide (YMLDLQPET), or HLA-A*0201 restricted HPV/E7(82-90) peptide (LLMGTLGIV). Assay media used was RPMI-1640 + 10% FBS. After an overnight (18-24h) incubation period, supernatant was collected from each well. IFN-γ concentration was analyzed using the Meso Scale Discovery IFN-γ assay.